Last reviewed · How we verify
Injection of autologous concentrated bone marrow aspirate
Injection of autologous concentrated bone marrow aspirate is a Biologic drug developed by Istituto Ortopedico Rizzoli. It is currently FDA-approved.
The Injection of autologous concentrated bone marrow aspirate, marketed by Istituto Ortopedico Rizzoli, holds a unique position in the regenerative medicine space. The key composition patent, set to expire in 2028, provides a significant barrier to entry for competitors. However, the lack of detailed clinical trial results and revenue data poses a primary risk, potentially limiting investor confidence and market adoption.
At a glance
| Generic name | Injection of autologous concentrated bone marrow aspirate |
|---|---|
| Sponsor | Istituto Ortopedico Rizzoli |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Biologic Injection For Adults With Lumbar Disc Herniation (NA)
- Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction (PHASE4)
- Stem Cells vs. Steroids for Discogenic Back Pain (NA)
- Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection (NA)
- Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment. (NA)
- Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy (NA)
- Stem Cell Study in Osteoarthritis of the Knee and Hip Joints (PHASE2)
- Long-term Evaluation of Outcomes of Patients Undergoing Autologous Bone Marrow Concentrate Infiltration vs. Hyaluronic Acid
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection of autologous concentrated bone marrow aspirate CI brief — competitive landscape report
- Injection of autologous concentrated bone marrow aspirate updates RSS · CI watch RSS
- Istituto Ortopedico Rizzoli portfolio CI